28 March
2024
Iconic Labs
PLC
("Iconic"
or the "Company")
Interim results for the six
months ended 31 December 2023
Iconic Labs PLC (LSE: ICON),
today announces its unaudited financial results for the six-month
period ended 31 December 2023.
Period Highlights:
§ August 2023, Prospectus published to
provide the Company with the ability to issue further Ordinary
Shares under the Prospectus Regulation Rules
§ September 2023, 83,256 Ordinary
Shares issued to all creditors under the CVA
§ October 2023, Iconic successfully
completed and satisfied all conditions of, and consequently exited,
the CVA
Post-Period
Highlights:
§ January 2024, Appointment of Victor
Humberdot and Bela Lendvai-Lintner as Non-executive
Directors
§ March 2024, Signed non-binding heads
of terms with ITS Holdings 2023 Ltd ("ITS"), the holder of the
entire issued share capital of In the Style Fashion Ltd, in
connection with potential purchase of ITS
Brad Taylor, Chief Executive Officer of Iconic Labs,
commented:
"The Company has made promising progress during
the first half of this financial year. Since we successfully
undertook our financial restructuring at the end of 2023, we have
satisfied the final condition to conclude the CVA and we pivoted
our strategy to focus on acquiring a suitable company through a
reverse takeover.
"Post-period end, we were pleased to announce the Company had
entered into a non-binding head of terms with the owners of ITS
Holdings 2023 Ltd, an online fashion retailer, which the Board and
I believe meets our strategic objectives of long-term growth and
value for our shareholders."
For any further
information or enquiries please contact:
Iconic Labs
Brad Taylor, Chief Executive
Officer
|
Tel: +44 (0) 7462 156238
ir@iconiclabs.co.uk
|
Novum Securities Limited
David Coffman / Daniel
Harris
|
Tel: +44 (0) 20 7399 9400
|
Yellow Jersey PR
Sarah Hollins
Annabelle Wills
Bessie Elliot
|
Tel: +44 (0) 20 3004
9512
iconic@yellowjerseypr.com
|
CHIEF EXECUTIVE OFFICER'S STATEMENT
I am pleased to present the interim
unaudited accounts for the six-month period ended 31 December 2023
for Iconic Labs PLC and its subsidiaries (together, "Iconic" or the
"Company").
Over the six-month period ended 31
December 2023 and as part of the requirements for the Company's
successful exit from administration and renewed trading on the
London Stock Exchange, the Company published a Prospectus on 8
August 2023 to provide the Company with the ability to issue
further Ordinary Shares under the Prospectus Regulation Rules as
follows:
(i)
Up to 1,674,130,609 Ordinary Shares to be issued to
unsecured creditors under the CVA;
(ii)
Up to 45,045,045,045 Ordinary Shares to be issued to
EHGOSF to convert £750,000 in convertible notes, and to Linton
Capital to convert £750,000 in convertible notes under the
Settlement Deed;
(iii)
Up to 80,180,180,180 Ordinary Shares to be issued to EHGOSF
to satisfy £2,670,000 in unconverted drawdowns and certain fees
pursuant to the Financing Facility;
(iv)
Up to 36,038,525,658 Ordinary Shares to be issued to EHGOSF
to satisfy the exercise of its Warrants under the Financing
Facility; and up to 22,027,027,027 Ordinary Shares to be issued to
Ott Ventures s.r.o and/or Ott Ventures USA, Inc. under the
Management Services Agreement for outstanding fees as of the date
of the prospectus totalling £665,000. As of 31 December 2023, an
additional £37,500 was outstanding for Chief Executive Officer and
executive compensation for the months of September through December
2023.
Since 30 June 2023, EHGOSF has
converted £580,000 of convertibles notes under the Financing
Facility resulting in the Company issuing a total of 689,655,172
Ordinary Shares of £0.00001 each and 5,609,526 Ordinary Shares of
£0.1 each, post consolidation, to EHGOSF.
The Company held its Annual General
Meeting ("AGM") on 25 August 2023 at which all resolutions were
duly passed, including a resolution for the consolidation of the
Company's Ordinary Shares on a 10,000 for 1 basis, such that every
10,000 Ordinary Shares of £0.00001 each were consolidated into 1
Ordinary Share of £0.1 each in nominal value.
Since the publication of the
Prospectus and the AGM, the Company was pleased to announce that it
had satisfied the final condition to bring the CVA to a successful
conclusion when it issued 83,256 Ordinary Shares of £0.1 each to
the creditors under the CVA. As of 21 September 2023, all documents
concluding the CVA had been filed with, and accepted by, Companies
House.
A further AGM was held on 13
February 2024 at which all the resolutions were duly passed,
including a resolution for the sub-division and conversion of each
existing Ordinary Share into one new ordinary share of £0.0001 in
the capital of the Company (a "New Ordinary Share") and one
deferred share of £0.0999 in the capital of the Company (a
"Deferred Share") (each such Deferred Share having no voting or
dividend rights and effectively being worthless) so that the
nominal value of a New Ordinary Share would be less than the price
of a share in the market, therefore allowing the Company to raise
funds going forward by issuing further shares, should the Directors
elect to do so.
As set in the August 2023
Prospectus, the Company intended to resume its historical revenue
generating offering by identifying companies in the online media,
artificial intelligence, and big data gathering, processing and
analysis sectors with which it could enter into advisory services
contracts. At the time, it was thought that such advisory services
could provide the Company with short-term revenues and news flow
while it continued to search for a suitable acquisition
target.
However, given the limited number of
personnel working with the Company, the time commitment needed to
properly provide advisory services to prospective clients, and
current market conditions, the Company decided that this
short-term strategy was no longer viable. As such it decided to
cease this strategy in favour of focusing all of its time,
resources, and energy on acquiring a suitable company through a
reverse takeover ("RTO") to generate long term growth and value for
its shareholders.
On 29 February 2024, due to a
significant share price movement on 28 February 2024 and the
suspension of trading in the shares by the FCA, the Company
confirmed that it was in discussions regarding a potential
acquisition which, should it proceed would constitute an RTO under
Listing Rule 5.6.
On 11 March 2024, the Company
confirmed that it had entered into non-binding heads of terms with
the owners of ITS Holdings 2023 Ltd, the holder of the entire
issued share capital of In the Style Fashion Ltd (the "Target"), an
online fashion retailer, in connection with the potential purchase
of the entire issued share capital of the Target (the
"Transaction"). The proposed Transaction is, inter alia,
conditional on the completion of legal and financial due diligence
on the Target. If completed, the Transaction would constitute an
RTO under the Listing Rules. As the Company was currently unable to
provide full disclosure under Listing Rule 5.6 in relation to the
Target, suspension of trading would continue until such time as a
prospectus was published in relation to the proposed acquisition or
the Company announces that the discussions have been
terminated.
No binding agreement had been
reached at the time of publication of these accounts and,
accordingly, the Directors of Iconic cannot guarantee that the
proposed Transaction would complete or provide any indication of a
likely completion date.
At present, the Company only has one
asset, GSN, a platform dedicated to providing media curated for the
LGBTQ+ community. The Company's strategic objective regarding GSN
is to relaunch it with the aim that it becomes the premier LGBTQ+
platform for news, social media, events, restaurants, travel, and
technology information.
GOING CONCERN ASSESSMENT
The Board of Directors has carefully
considered the financial position of Iconic regarding the events
during the six months ended 31 December 2023, with particular focus
on the new Financing Facility with EHGOSF and its obligations under
the Settlement Deed. We have concluded that Iconic remains a going
concern.
PRINCIPAL RISKS AND UNCERTAINTIES
The following risks are considered by the Board to be the most significant
to the business:
RTO
Target Risk
Iconic has identified and announced
a target for a proposed RTO, however there is a risk that the RTO
will not complete.
Revenue, Profitability and Funding Risk
Iconic currently is not
cash-generative and is therefore reliant upon the Financing
Facility with EHGOSF for its sole source of working
capital.
The Financing Facility is subject to
a number of conditions ("Conditions") including in
particular:
(a) The shares
of Iconic trade on the Main Market of the London Stock
Exchange;
(b) The closing
market price of the Shares for each of the ten consecutive trading
days falling immediately prior to the relevant closing date must be
at least higher than 150% of the nominal value of Iconic's
shares;
(c) The average daily
value traded of Iconic's shares (excluding 5% of the data points
from the top and excluding 5% of the data points from the bottom of
the data set) for the 20 trading days immediately prior to the
applicable closing date must be at least £10,000;
(d) From the
fifth drawdown tranche onwards, Iconic having published a
Prospectus;
(e) No binding
commitment has been entered into by Iconic pursuant to which a
change of control in Iconic would occur;
(f) No
occurrence that constitutes an event of default having occurred and
is continuing;
(g) The
Board having the required authority;
(1) For the allotment and issue of
at least 200% of such number of Shares as would be required upon
conversion of all outstanding Notes together with the Notes to be
issued pursuant to the relevant drawdown notice calculated by
dividing the aggregate principal amount of all such Notes by the
Closing VWAP as of the date of such drawdown notice; and
(2) To deviate from the
Shareholders' pre-emption and/or preferential subscription right
(as applicable) with respect to such number of Shares;
and
No payment is due by the Company to
EHGOSF (or any of its Affiliates) and no delivery of Shares (or
certificates evidencing such Shares) resulting from a conversion of
Notes or exercise of any Warrants by EHGOSF (or any of its
Affiliates) is outstanding.
Iconic maintains a
limited amount of cash on its account as it relies
entirely at this time on the EHGOSF financing facility to meet its
operational expenditures. There currently remains approximately
£1.75 million available for drawdown under the Financing Facility.
The expected ordinary course cash burn of the business is
approximately £125,000 per month for the next 12 months, the
substantial majority of which will be spent on RTO
expenses.
At present, conditions (b) (c) and
(f) have not been met, and it is possible that in the future
certain other such conditions may not be met, some of which are
outside the control of the Company. It is therefore not currently
known when this may happen. To date, EHGOSF has agreed to waive
breaches of these conditions, on certain agreed terms. As a result,
in the event any such condition is not met, the Company may not be
in a position to further drawdown on the Financing Facility.
Although the Directors would endeavour to pursue certain options to
mitigate the consequence of such breach there is no certainty that
any such options could be achieved either in part or at all. In
such an event the Company would need to wind down its operations,
realise any assets and may enter administration, if and to the
extent there are creditors of the Company who cannot be paid. In
such an event, the Company would no longer manage the affairs of
the Company or the realisation of its assets. As a result of either
winding down the business or entering into administration, the
Ordinary Shares would be cancelled from the Official List and
Shareholders may receive little or no value for their Ordinary
Shares.
Dilution and Pricing Risk
If EHGOSF exercises its full rights
under the Financing Facility for conversion of Loan Notes and
Warrants into Shares, this could result in a significant holding in
the Company by EHGOSF. However, EHGOSF's strategy is generally to
sell shares in the market as soon as practicable following the
exercise of such rights and in any event under the Financing
Facility, inter alia, EHGOSF cannot hold more than 29.9% of the
Company. Accordingly, there is a risk that should the Company seek
to drawdown under the Loan Notes and EHGOSF thereafter exercise and
sell Shares in significant amounts over a lengthy period, this
could have a material negative impact on the price of the
Shares.
Key
Executive Risk
Given the wholesale change in the
Board of Directors and executive team in January 2024, there is a
risk of Iconic not being able to retain key executives, which could
adversely affect Iconic's operating and financial performance.
Retaining and motivating Bradley Taylor (Chief Executive Officer)
is a critical component of the future success of the
business.
Global Economic
Risk
The online media and publishing,
technology, artificial intelligence, and data gathering,
processing, and analytics sectors are susceptible to adverse
developments in the global economy and particularly the UK economy
where Iconic is located. The continual uncertainty over the war in
Ukraine, the high inflationary environment and the threat of global
recession, for example, may continue to delay spending by potential
clients which may have a negative effect on the demand for services
which could affect Iconic's revenues.
Potential Unrecorded Legacy Liabilities
As evidenced by the administration
and disputes involving various key parties, there were significant
legacy issues that predated management's arrival. Following the
exit from administration and the entering into of confidential
settlement agreements with various parties, the Directors consider
that it is unlikely that there are any material unknown liabilities
of Iconic, however there is the potential for unknown creditors to
emerge which would increase the liabilities of the
Company.
Inability to contract with customers on the most favourable
terms
The Company enters into contracts
with a wide variety of companies, many of whom possess greater
negotiating leverage than is currently available to the Company.
The Company may be required to tolerate terms which are less
favourable than might be anticipated, and which may also be
governed by the laws of other jurisdictions, and this could
intensify if the number of competitors increases, thereby
potentially giving existing or prospective customers more options.
Furthermore, if the Company enters into more onerous terms than it
would ideally enter into, it may risk not being able to satisfy
those terms. Breaching onerous terms or failing to secure the best
commercial terms possible could have a material impact on the
Company's business revenue, financial condition and
profitability.
Access to further capital
Part of the Company's growth
strategy is to identify and acquire similar businesses that are of
a smaller scale and which are well-priced. In the longer term, the
Company is intending to grow the business organically and continue
to identify and acquire similar businesses, albeit the Company
anticipates such future acquisitions to be of a larger scale than
those the Company is looking to make in the near term. The
Company's longer term growth strategy may require additional funds
in order to respond to business challenges, enhance existing
services and complete any future acquisitions.
Accordingly, the Company may need to
engage in equity or debt financings to secure additional funds. If
the Company raises additional funds through further issues of
equity or convertible debt securities, existing shareholders could
suffer significant dilution, and any new equity securities could
have rights, preferences, and privileges superior to those of
current shareholders. Any debt financing secured by the Company in
the future could involve restrictive covenants relating to its
capital raising activities and other financial and operational
matters, which may make it more difficult for the Company to obtain
additional capital and to pursue business opportunities, including
potential acquisitions. In addition, the Company may not be able to
obtain additional financing on terms favourable to it, if at all. If the
Company is unable to obtain adequate financing or financing on
terms satisfactory to it, when required, its ability to continue to
support its business growth and to respond to business challenges
could be significantly limited or could affect its financial
viability
Financial Risk Management
The Board monitors the internal risk
management function across Iconic and advises on all relevant risk
issues. There is regular communication with internal departments,
external advisors and regulators.
FINANCIAL REVIEW
Iconic made a profit in the 6 month
period of £270,131 (2022 - £5,480,355), which is attributable to
the reduction in administrative expenses (decreased by £384,503
compared to the same period last year). The decrease is mainly due
to the writing back of creditors balances which are no longer due
and the creditor settlements under the CVA.
At 31 December 2023, Iconic held
total assets of £14,175 (2022 - £92,895). The Group had liabilities
of £2,756,504 at the balance sheet date (2022 - £3,551,059), a
decrease of £794,555.
Key
Performance Indicators
The business is focused on the areas
of cash management and operating results.
Iconic has identified the following
key performance indicators which the Directors will use to measure
success against the business plan:
· Gross
revenue growth
· EBITDA
growth
· Market
value
RESPONSIBILITY STATEMENT
The directors confirm to the best of
our knowledge:
·
the interim financial statements have been
prepared in accordance with IAS 34, as adopted by the European
Union
·
the Chairman's statement and interim financial
statements include a fair review of the information required by the
Financial Statements Disclosure and Transparency Rules (DTR)
4.2.7R, being an indication of important events that have occurred
during the first six months of the financial year and a description
of the principal risks and uncertainties for the remaining six
months of the year; and
·
the Chairman's statement includes a fair review of
the information required by DTR 4.2.8R, being related party
transactions that have taken place in the first six months of the
current financial year and that have materially affected the
financial position or performance of the entity during the period
and also any changes in the related party transactions described in
the last annual report that could do so.
At the date of this statement, the
Directors are those listed on the Company information page of these
interim financial statements.
3. Share
capital
|
31
December 2023
|
30 June 2023
|
|
|
Number
|
£
|
Number
|
£
|
|
Allotted,
issued and fully paid:
|
|
|
|
|
|
Classified as equity
|
|
|
|
|
|
Ordinary
shares of £0.00001 each
|
-
|
-
|
46,306,916,660
|
463,069
|
|
Ordinary
shares of £0.10 each
|
10,306,783
|
1,030,678
|
-
|
-
|
|
Deferred
shares of £0.00249 each
|
1,637,129,905
|
4,076,454
|
1,637,129,905
|
4,076,454
|
|
Total
|
1,647,436,688
|
5,107,132
|
47,944,046,565
|
4,539,523
|
|
|
|
At 30 June
2023, the Company had 46,306,916,660 Ordinary shares of £0.00001 in
issue.
In August
2023, the Company issued 689,655,172 Ordinary shares of £0.00001
for £0.000039 each in respect of a conversion of loan notes by
EHGOSF.
Following
the share issue above, the Company undertook a share
consolidation. For every 10,000 £0.0001 Ordinary shares
held, the shareholder received 1 Ordinary share of £0.10. In order
to facilitate this consolidation, the Company had to issue 8,168
Ordinary shares of £0.0001 prior to the consolidation.
In
September 2023, the Company issued 220,361 Ordinary shares of £0.10
each for £0.23 each, 236,406 were issued for £0.13 each and 271,739
were issued for £0.11 each. These issues were all in respect of the
conversion of loan notes by EHGOSF. The Company also issued 83,256
Ordinary shares at par, to creditors as part of the CVA
arrangement.
In October
2023, the Company issued 1,508,110 Ordinary shares of £0.10 each at
par, in respect of the conversion of £130,000 loan notes by EHGOSF,
and related conversion fees.
In November
2023, the Company issued 1,022,490 Ordinary shares of £0.10 each at
par, in respect of the conversion of £50,000 loan notes by EHGOSF,
and related conversion fees. Also in November 2023, the Company
issued 769,043 Ordinary shares of £0.10 each at par, in respect of
the conversion of £35,000 loan notes by Linton Capital, and related
conversion fees.
In December
2023, the Company issued 1,495,720 Ordinary shares of £0.10 each at
par, in respect of the conversion of £70,000 loan notes by EHGOSF,
and related conversion fees.
At 31
December 2023, the Company had 10,306,783 Ordinary shares of £0.10
in issue.
4. Trade and other
payables
Group
|
31
December 2023
|
31 December 2023
|
30 June
2023 (audited)
|
|
£
|
£
|
£
|
Trade
payables
|
868,266
|
1,531,059
|
1,704,142
|
Other
payables
|
1,400
|
520,000
|
-
|
Accruals
|
59,438
|
-
|
45,999
|
|
929,104
|
2,051,059
|
1,750,141
|
|
|
|
|
Company
|
31
December 2023
|
31 December 2023
|
30 June
2023 (audited)
|
|
£
|
£
|
£
|
Trade
payables
|
868,266
|
1,531,062
|
1,704,142
|
Other
payables
|
1,400
|
520,000
|
-
|
Accruals
|
59,438
|
-
|
45,999
|
|
929,1047
|
2,051,062
|
1,750,141
|
Book values approximate to fair values at 31 December 2023 and 30
June 2023.
Included
within liabilities were £1,071,444 of unsecured creditors which
were under CVA proceedings at 30 June 2023. These were settled in
common shares of Iconic Labs in the ration of 1:0.25. This denoted
that 1GBP of liability was settled with 0.25GBP value in shares on
0.00016GBP per share value. These settlements were proceeded when
the company paid all of its secured creditors during 2Q
2023.
5. Financial
instruments
Reconciliation of movement in net cash
|
Net
cash at 1 July 2023
|
Cash
flow
|
Loan
notes issued in the period
|
Loan
notes converted in the period
|
Net
cash
at
31 December 2023
|
|
£
|
£
|
£
|
£
|
£
|
Cash at
bank and in hand
|
50,243
|
(49,136)
|
-
|
-
|
1,107
|
Borrowings
|
(1,940,000)
|
-
|
(302,400)
|
415,000
|
(1,827,400)
|
|
|
|
|
|
|
Total financial
liabilities
|
(1,889,757)
|
(49,136)
|
(302,400)
|
415,000
|
(1,826,293)
|
|
|
|
|
|
|
6. Profit from Operations
|
|
Period
ending 31 December 2023
|
Period ending 31 December 2022
|
Year ended 30 June
2023 (audited)
|
|
|
£
|
£
|
£
|
The
(Profit)/loss for the period is stated after charging:
|
|
|
|
Auditors
remuneration - audit services
|
34,200
|
58,725
|
30,000
|
|
|
|
|
Expenses by Nature:
|
£
|
£
|
£
|
Legal &
audit fees
|
163,395
|
72,953
|
772,578
|
Financial
advisory
|
-
|
7,500
|
-
|
Consultancy
& professional fees
|
54,064
|
515,000
|
433,368
|
Other
supplies and external services
|
22,807
|
5,251
|
112,957
|
Creditor's
write off
|
(739,133)
|
(6,139,324)
|
(6,117,482)
|
|
|
|
|
Total operating expenses
|
(464,667)
|
(5,479,895)
|
(4,768,579)
|
Total administrative
expense
|
(464,667)
|
(5,479,895)
|
(4,768,579)
|
Direct
costs incurred in connection with financing facilities
|
194,536
|
-
|
-
|
|
|
|
|
|
|
(270,131)
|
(5,479,895)
|
(4,768,579)
|